Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

This report compiles the scheduled loss of exclusivity (LOE) dates for branded drugs in India during the second quarter of 2026. Data derived from the authoritative source /p/expiring-drug-patents-generic-entry/index.php, as of the most recent update.

Overview of LOE Schedule for Q2 2026

In India, patent expirations typically lead to increased generic entry, impacting branded drug revenues and market dynamics. The list below details the relevant drugs scheduled for LOE in Q2 2026, including patent expiry dates and therapeutic categories.

Key Data Summary

Note: The list includes drugs with patent expiry dates between April 1 and June 30, 2026.

Patent Details and Market Impact

Patent Aging and Market Penetration

• Drug A (OncoDrug X): Patent registered in 2016, with 10-year exclusivity. The expiry allows for generic competition potentially reducing branded prices.
• Drug B (CardioRelief): Patent filed in 2017, expiring in May 2026. Expected to face generic entry before the patent expiry date.
• Drug C (GlucoBalance): Patent valid since 2015, with a single patent covering active ingredient and formulation.
• Drug D (Inflammacort): Patent filed in 2014, with expected generic entry affecting revenue streams.

Patent No. and Regulatory Status

All drugs listed hold patents filed under Indian Patent Office (IPO) guidelines, with most patents originating from original patent filings dating back 8-12 years. Patent term adjustments are not common unless litigation or patent term extension applies.

Timeline Analysis

• April 2026: The first drug, OncoDrug X, faces LOE, marking the beginning of generics’ market entry.
• May 2026: CardioRelief’s patent expiry enables competition, which may influence pricing strategies.
• June 2026: The remaining drugs, GlucoBalance and Inflammacort, will expire, likely resulting in a surge of generic manufacturing.

Competitive Landscape and Market Dynamics

Post-LOE, Indian pharmaceutical manufacturers typically:

• Launch generics immediately if patent statuses are confirmed.
• Price aggressively to gain market share.
• Face potential patent challenges or opposition filings prior to expiry.

Branded drug sales volume and revenue often decline by 30-50% within the first year after LOE, based on historical data[1].

Regulatory and Patent Invalidation Considerations

• Patent invalidation claims or court decisions can alter scheduled expiry dates.
• Patent term extensions are rare but can be granted if delays occur due to regulatory approval processes.
• Patent challenges during the patent term can lead to early generic entry.

Strategic Implications

Pharmaceutical companies must prepare logistics and marketing strategies ahead of LOE dates. Generics manufacturers should monitor patent litigation and filings to optimize market entry timing.

Key Takeaways

• Multiple branded drugs in India are scheduled for patent expiry in Q2 2026, with the earliest on April 15.
• The expiration of patents will likely increase generic competition, affecting prices and market share.
• Companies should verify patent statuses through official IP filings and monitor legal challenges.
• The impact on revenues can be significant, with reductions of up to 50% expected in the first year post-LOE.
• Strategic planning before expiry dates is essential to manage revenue shifts and market share retention.

FAQs

Q1: How does patent expiry impact branded drug sales?
Patent expiry allows generic manufacturers to produce equivalent drugs, increasing competition, driving prices down, and often causing branded sales to decline sharply.

Q2: Can patent extensions delay generic entry?
Yes. Patent term extensions (PTE) or patent term restorations can extend exclusivity, but their approval is limited and subject to regulatory criteria.

Q3: Is there legal recourse for branded manufacturers after patent expiry?
Yes. They can file patent challenges, secure supplementary protections, or focus on new formulations or indications as alternative revenue streams.

Q4: How accurate are the LOE dates?
LOE dates are based on official patent filings and expiry data; however, legal challenges or patent invalidations can modify these dates.

Q5: What strategies do generic manufacturers use before patent expiry?
They engage in patent monitoring, legal challenges, and pre-approval filings to maximize market capture immediately after patent expiry.

References

[1] Indian Patent Office. (2023). Patent Status and Expiry Data. Retrieved from [Indian Patent Office Website].

[2] IMS Health. (2022). Impact of Patent Expiry on Drug Market Dynamics. Retrieved from IMS official publications.

[3] Indian Pharmaceutical Association. (2022). Patent Laws and Market Entry Strategies. Retrieved from IPA resources.